February 16th 2022
February 15th 2022
February 15th 2022
FDA Approves Paxlovid for COVID-19 in Adults, Continues Strategy to Minimize Infection SeverityMay 25th 2023
This is the first oral antiviral to get through the regulatory process and is indicated for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19, including hospitalization or death.
Evaluating the Benefits and Risks of Fecal Microbiota Transplantation for Recurrent C diffMay 25th 2023
FMT is a promising intervention for immunocompetent patients with recurrent C difficile infection. However, the safety of FMT remains inconclusive due to limited data on serious adverse events and mortality.
FDA Approves Sulbactam-Durlobactam for Bacterial PneumoniaMay 23rd 2023
The antibiotic, marketed as Xacduro, is indicated for hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by susceptible strains of bacteria called Acinetobacter baumannii.
“A Gamechanger to how Pediatric Care Is Conducted”: RSVpreF Vaccine Could Reduce RSV in Infants by Over 80%May 22nd 2023
Pfizer's RSVpreF vaccine candidate has shown promising efficacy in preventing severe lower respiratory illness caused by RSV in infants. With the potential approval of RSVpreF, pediatric care could undergo a significant positive change.
Expanding HCV Care: Effectiveness of Accessible Testing and Treatment for People Who Inject DrugsMay 20th 2023
By implementing rapid point-of-care HCV RNA testing in supervised consumption services, a study achieved high testing acceptance and successful engagement with HCV care among individuals who inject drugs.
FDA Advisory Committee Affirms Safety and Efficacy of Pfizer RSVpreF VaccineMay 19th 2023
RSVpreF receives strong support from the FDA's VRBPAC, with positive votes for efficacy and safety. The vaccine shows promise in preventing severe respiratory illness in infants, and an FDA authorization decision is expected in August 2023.
AI-Driven Advancements Pave the Way to Test for COVID-19 and Hepatitis at HomeMay 18th 2023
These new tests, conducted in a single tube within minutes, could enable at-home testing for various diseases. By incorporating CRISPR technology, the test achieves high reliability by distinguishing between false and true positives.
LMN-201 Fast Tracked by FDA as a Potential Breakthrough Treatment for C diff InfectionMay 17th 2023
LMN-201, an oral biologic drug developed by Lumen Bioscience, has received Fast Track Designation from the FDA. The drug combines therapeutic proteins to neutralize the bacterium and toxin that cause C difficile infection.
Using AI as a Tool for Infectious Disease SurveillanceMay 17th 2023
AI tools have taken front and center stage in 2023. One area of interest is how the new technology can be applied in infectious disease surveillance. A new article in the New England Journal of Medicine explores this concept.